Autoantibodies and serum inhibition factors (SIF) in patients with myocarditis

Maisch, Bernhard; Berg, Peter A.; Kochsiek, K

doi:10.1007/bf01476967

Cited by 40 publications

(16 citation statements)

References 29 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The concept of immunopathogenesis of conduction disorders may also be applied to postmyocarditic heart diseases [32,37,42], perimyocarditis [32,35,36,37,42] and post-pericardiotomy syndrome [34] in the future. It indicates that not only the myocardium but also the cardiac conducting system can be the target in the secondary immunopathogenesis.…”

Section: Discussionmentioning

confidence: 99%

Humoral immune response to cardiac conducting tissue

Lotze

Maisch

1989

Springer Semin Immunopathol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Humoral immune response to cardiac conducting tissue

Lotze

Maisch

1989

Springer Semin Immunopathol

View full text Add to dashboard Cite

“…and antibodies directed against the capillaries and the endothelium of small vessels (AEA). A heterologous renal tubular immunofluorescent pattern associated with a positive antisarcolemmal and antiendothelial reaction was attributed to heterophil antibodies [26,28] and was therefore excluded. Antibodies against double-stranded DNA were tested radioimmunologically (Amersham).…”

Section: Immunological Investigationsmentioning

confidence: 99%

“…Muscle-specific and nonorgan-specific autoantibodies and AMLA in particular have been described in several cardiac diseases: rheumatic carditis [23], viral myopericarditis [26,28], infective endocarditis [unpublished] and postpericardiotomy and postinfarction syndromes [25], In patients with 'uremic' pericarditis, immunological in vestigations have not yet been performed. Our studies clearly demonstrate the presence of ASA, and the musclespecific subtype AMLA, in patients with myocarditis in the context of renal failure: whereas the frequency of AMLA in patients on dialysis without pericarditis was below 5% AMLA were frequently observed in patients with pericarditis on long-term dialysis (group 2) and reg ularly in patients with pericarditis in chronic or acute glo merulonephritis leading to renal failure.…”

Section: Diagnostic and Pathogenetic Significance Of A Ntimyocardial mentioning

confidence: 99%

Humoral Immune Reactions in Uremic Pericarditis

Maisch¹,

Kochsiek²

1983

Am J Nephrol

View full text Add to dashboard Cite

Clinical data from 41 patients with pericarditis or pericardial effusion in acute and chronic renal failure were analyzed in respect to the diagnostic relevance of humoral immune reactions. In patients with pericardial effusion in acute renal failure due to surgery or trauma (n = 10), antimyocardial antibodies were rarely detected. In contrast, in the sera of all patients with pericarditis or pericardial effusion following renal failure in chronic or acute glomerulonephritis (n = 6), complement-fixing antisarcolemmal antibodies of the IgM and IgG classes were observed. In patients in whom pericarditis or pericardial effusion evolved during chronic hemodialysis (n = 25), the incidence of complement-fixing antimyolemmal antibodies was 64%. Only sera with complement-fixing antimyolemmal antibodies induced cytolysis of vital adult cardiocytes in vitro suggesting that the antimyolemmal antibodies may not only play a diagnostic but also a pathogenetic role in ‘uremic’ pericarditis in vivo.

show abstract

“…Postinfectious myocarditis is a relatively rare sequela of acute viral myocarditis and has been attributed to autoimmune pro cesses [Maisch et al, 1980[Maisch et al, , 1983Woodruff, 1980;Wolfgram et al, 1985Wolfgram et al, , 1986. Maisch et al [1980] observed that serum of some patients with postviral myocarditis reacted with sarcolemmal and cytoplasmic heart an-' Supported by PHS grant No.…”

Section: Introductionmentioning

confidence: 99%

“…Maisch et al [1980] observed that serum of some patients with postviral myocarditis reacted with sarcolemmal and cytoplasmic heart an-' Supported by PHS grant No. HL-33878 from the National Institutes of Health.…”

Section: Introductionmentioning

confidence: 99%